Vyxeos versus 7 + 3 for Older Patients with High-Risk AML

Vyxeos versus 7 + 3 for Older Patients with High-Risk AML

User Photo
moffitt

3 years
1,018 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jeffrey E. Lancet, MD of Moffitt Cancer Center gives an overview of a phase 3 randomized trial, which focused on the use of vyxeos (CPX-351) compared to cytarabine and daunorubicin (7+3) in older patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Up Next Autoplay
>